Verduijn J, Milaneschi Y, Schoevers R A, van Hemert A M, Beekman A T F, Penninx B W J H
Department of Psychiatry, EMGO Institute for Health and Care Research and Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Transl Psychiatry. 2015 Sep 29;5(9):e649. doi: 10.1038/tp.2015.137.
Meta-analyses support the involvement of different pathophysiological mechanisms (inflammation, hypothalamic-pituitary (HPA)-axis, neurotrophic growth and vitamin D) in major depressive disorder (MDD). However, it remains unknown whether dysregulations in these mechanisms are more pronounced when MDD progresses toward multiple episodes and/or chronicity. We hypothesized that four central pathophysiological mechanisms of MDD are not only involved in etiology, but also associated with clinical disease progression. Therefore, we expected to find increasingly more dysregulation across consecutive stages of MDD progression. The sample from the Netherlands Study of Depression and Anxiety (18-65 years) consisted of 230 controls and 2333 participants assigned to a clinical staging model categorizing MDD in eight stages (0, 1A, 1B, 2, 3A, 3B, 3C and 4), from familial risk at MDD (stage 0) to chronic MDD (stage 4). Analyses of covariance examined whether pathophysiological mechanism markers (interleukin (IL)-6, C-reactive protein (CRP), cortisol, brain-derived neurotrophic factor and vitamin D) showed a linear trend across controls, those at risk for MDD (stages 0, 1A and 1B), and those with full-threshold MDD (stages 2, 3A, 3B, 3C and 4). Subsequently, pathophysiological differences across separate stages within those at risk and with full-threshold MDD were examined. A linear increase of inflammatory markers (CRP P=0.026; IL-6 P=0.090), cortisol (P=0.025) and decrease of vitamin D (P<0.001) was found across the entire sample (for example, from controls to those at risk and those with full-threshold MDD). Significant trends of dysregulations across stages were present in analyses focusing on at-risk individuals (IL-6 P=0.050; cortisol P=0.008; vitamin D P<0.001); however, no linear trends were found in dysregulations for any of the mechanisms across more progressive stages of full-threshold MDD. Our results support that the examined pathophysiological mechanisms are involved in MDD's etiology. These same mechanisms, however, are less important in clinical progression from first to later MDD episodes and toward chronicity.
荟萃分析支持不同病理生理机制(炎症、下丘脑 - 垂体(HPA)轴、神经营养生长和维生素D)参与重度抑郁症(MDD)。然而,当MDD进展为多次发作和/或慢性化时,这些机制的失调是否更明显仍不清楚。我们假设MDD的四种核心病理生理机制不仅参与病因,还与临床疾病进展相关。因此,我们预期在MDD进展的连续阶段中会发现越来越多的失调。荷兰抑郁与焦虑研究(年龄18 - 65岁)的样本包括230名对照和2333名参与者,这些参与者被纳入一个临床分期模型,该模型将MDD分为八个阶段(0、1A、1B、2、3A、3B、3C和4),从MDD的家族风险(0期)到慢性MDD(4期)。协方差分析检验了病理生理机制标志物(白细胞介素(IL)-6、C反应蛋白(CRP)、皮质醇、脑源性神经营养因子和维生素D)在对照组、有MDD风险者(0、1A和1B期)以及完全阈值MDD患者(2、3A、3B、3C和4期)中是否呈现线性趋势。随后,研究了有风险者和完全阈值MDD患者不同阶段之间的病理生理差异。在整个样本中(例如,从对照组到有风险者和完全阈值MDD患者)发现炎症标志物(CRP P = 0.026;IL - 6 P = 0.090)、皮质醇(P = 0.025)呈线性增加,维生素D呈线性下降(P < 0.001)。在针对有风险个体的分析中存在跨阶段失调的显著趋势(IL - 6 P = 0.050;皮质醇P = 0.008;维生素D P < 0.001);然而,在完全阈值MDD更进展阶段的任何机制失调中均未发现线性趋势。我们的结果支持所研究的病理生理机制参与MDD的病因。然而,这些相同的机制在从首次到后期MDD发作以及向慢性化的临床进展中不太重要。